MedTech Dive June 10, 2024
Elise Reuter

Abbott will launch two over-the-counter glucose monitors in the U.S., competing directly with Dexcom’s Stelo.

Dive Brief:

  • Abbott said Monday it will launch two over-the-counter continuous glucose monitors after receiving clearance from the Food and Drug Administration.
  • One product is the company’s Lingo device, sold as a wellness product for people who do not have diabetes. The other is Abbott’s new Libre Rio device, which is intended for adults with Type 2 diabetes who do not use insulin, posing a direct challenge to Dexcom’s Stelo device.
  • After Lingo was cleared last week, RBC Capital Markets analyst Shagun Singh wrote the over-the-counter nod could offer a more than $1 billion sales opportunity for Abbott.

Dive Insight:

Abbott had...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, FDA, Govt Agencies, Medical Devices, Technology, Wearables
Related Articles:
FDA names Tarver as new head of device center
That’s a wrap: 5 takeaways from The Medtech Conference
Beyond Neurotech: Limits of BCI For People With Disability
Tarver named new director of FDA’s device center
UK Government sets out roadmap for circular economy in MedTech

Share This Article